Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBIT Margin: 2020-2025

Historic EBIT Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -98.56%.

  • Maravai Lifesciences Holdings' EBIT Margin rose 14137.00% to -98.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -100.90%, marking a year-over-year decrease of 2681.00%. This contributed to the annual value of -90.91% for FY2024, which is 7995.00% down from last year.
  • Maravai Lifesciences Holdings' EBIT Margin amounted to -98.56% in Q3 2025, which was up 29.52% from -139.84% recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' EBIT Margin ranged from a high of 75.87% in Q3 2021 and a low of -239.93% during Q3 2024.
  • Its 3-year average for EBIT Margin is -67.73%, with a median of -29.39% in 2024.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' EBIT Margin slumped by 21,688bps in 2024, and later soared by 14,137bps in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBIT Margin (Quarterly) stood at 67.65% in 2021, then crashed by 1,428bps to 53.37% in 2022, then tumbled by 6,301bps to -9.64% in 2023, then slumped by 5,702bps to -66.66% in 2024, then spiked by 14,137bps to -98.56% in 2025.
  • Its EBIT Margin stands at -98.56% for Q3 2025, versus -139.84% for Q2 2025 and -104.93% for Q1 2025.